BOEHRINGER-INGELHEIM
14.9.2020 14:03:10 CEST | Business Wire | Press release
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrated BI 425809 has met its primary endpoint. The data showed improvement in cognition in stable adult patients with schizophrenia.1 Central to many everyday tasks, impairment of cognitive function still constitutes a major burden for patients, and no pharmacological treatments are currently approved for cognitive impairment associated with schizophrenia (CIAS). These results presented at the 33rd European College of Neuropsychopharmacology (ECNP) Congress will advance the understanding of how deficits in transmission of signals between nerve cells may contribute to diminishing cognition in people living with schizophrenia.2
The Gly-T1 inhibitor, BI 425809, forms a key component of Boehringer Ingelheim’s Central Nervous System (CNS) research program. The latest trial results, along with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, will help determine the direction for BI 425809 in further schizophrenia research.3,4
Prof. W. Wolfgang Fleischhacker, Medical University Innsbruck, Austria: “The outcome of this trial is an important step forward in our understanding of cognition in schizophrenia. Cognitive impairment causes significant challenges for people in their everyday functioning. Patients with schizophrenia struggle with remembering things like birthdays, learning new tasks, concentrating, or making decisions that affect their everyday life. Advancing our understanding of how we might improve these symptoms in schizophrenia is significant for the research community and the patients and families living with this condition.”
The Phase II results of BI 425809 in cognitive impairment associated with schizophrenia are being further evaluated to assess how they will support the continued research and development for the treatment of schizophrenia.
“The trial results for our investigational compound BI 425809 in schizophrenia are encouraging. This is a positive advancement in our mechanistic knowledge of how excitatory neurotransmissions affect aspects of mental illness, aligning with our systematic neurobiological approach to CNS research,” adds Dr Vikas Mohan Sharma, M.D., head of medicine CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim. “We recognize this is important news for people affected by schizophrenia. We are making progress in developing treatments which will not only reveal important advances in our understanding of schizophrenia but also potentially other neuropsychiatric diseases.”
Cognition is a fundamental aspect of everyday life, including problem solving, memory and attention. When affected, people living with poor cognition can have a reduced mental ability to process information, remember straightforward things or perceive other people’s emotions and expressions. These functions are common to many forms of mental disorders such as schizophrenia, Alzheimer’s disease and depression. Finding solutions for cognitive impairment is a key area of Boehringer Ingelheim CNS research.
~ENDS~
For references and notes to editiors, please visit: http://www.boehringer-ingelheim.com/press-release/phase-ii-results-cognitive-impairment-schizophrenia
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mindbreeze InSpire Reduces Token Maxxing, Turning Runaway AI Costs Into Predictable Enterprise Value28.7.2026 15:03:00 CEST | Press release
By grounding generative AI in precise, governed enterprise knowledge, Mindbreeze InSpire cuts the wasted tokens that inflate AI budgets and erode answer quality. Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that Mindbreeze InSpire reduces token maxxing, the costly overconsumption of large language model (LLM) tokens that is straining enterprise AI budgets. By retrieving only the most relevant, grounded content and passing it to LLMs with precision, Mindbreeze InSpire lowers the tokens required per answer while improving accuracy, giving enterprises a path to scalable AI with predictable economics. Token maxxing has become one of the most underestimated risks in enterprise AI. As organizations connect generative AI to their data, many default to injecting large volumes of undifferentiated context into every prompt, repeatedly, across thousands of queries. Industry analysis has warned that tokens are becoming the true unit of AI cost,
Uptime Institute 16th Annual 2026 Global Data Center Survey: Deployment of High Density Racks Rising Fast, Operators Face Continued Recruiting and Retention Pressures28.7.2026 15:02:00 CEST | Press release
Uptime Institute today released the findings of its 16th Annual Global Data Center Survey, the most comprehensive study of the digital infrastructure sector. The 2026 results reveal an industry navigating workforce constraints, escalating outage expenses, even as rising costs remain the top concern for management teams. Financial Pressure and Resource Constraints Intensify: While high costs continue to be a primary concern for data center leaders, the 2026 survey also highlights escalating concerns over capacity forecasting, power availability, and supply chain disruptions. Power efficiency gains remain gradual. The industry saw minor improvements in average Power Usage Effectiveness (PUE) levels this year. While newer facilities may boast highly efficient designs, overall global progress is slowed by legacy infrastructure. The AI and Density Reality Check: Despite market enthusiasm for Artificial Intelligence, expectations for AI in data center operations cooled slightly in 2026. Oper
Torq Unveils the SOC Brain: The AI SOC That Learns, Not Just Remembers28.7.2026 15:00:00 CEST | Press release
New Torq AI SOC Platform layer’s innovative capabilities learn from every security decision and historical incident, drawing conclusions from precedents and team judgments from day zero Torq, the established agentic security operations leader, today introduced Torq SOC Brain™, a new layer of the Torq AI SOC Platform that continuously learns from historical investigations, analyst decisions, and organization-specific security operations to create a unified, self-learning AI SOC. While most autonomous investigation systems claim to be self-learning, they are, in reality, memory systems—they simply retrieve past cases and pass them to a language model at decision time. Torq SOC Brain is fundamentally different. It reasons from precedent, adapts to how each SOC evaluates risk, and continuously refines its judgment with every completed investigation. The result is an AI SOC that grows more accurate over time—not a thin wrapper around a generic AI model. This press release features multimedi
AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street28.7.2026 15:00:00 CEST | Press release
Japan’s leading automotive aftermarket retailer uses Rimini Smart Path™ to accelerate innovation without disrupting its core SAP ECC and Oracle Database systems Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that AUTOBACS SEVEN Co., Ltd. celebrates its 10-year partnership with Rimini Street, marking a decade of stable core operations and reinvestment in innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728266493/en/ AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street Since switching to Rimini Support™ for SAP ECC 6 in 2016, AUTOBACS SEVEN has expanded its partnership to include Oracle Database, helping the company stabilize mission-critical systems, reduce maintenance burden and free resources for innovation. “At AUTOBACS SEVEN, our lea
Abnormal AI Extends its Behavioral Security Platform to Identity and AI Security28.7.2026 15:00:00 CEST | Press release
Abnormal launches three new products: Identity Threat Protection, AI Governance, and Infiltration Prevention to secure the modern identity attack surface Abnormal AI, the AI-native behavior security company trusted by more than 25% of the Fortune 5001, today announced the expansion of its Behavioral Security Platform across the enterprise, introducing three new products: Identity Threat Protection, AI Governance, and Infiltration Prevention. Together, the launch extends the behavioral AI that already secures over 4,500 customers1 to the identities, AI systems and onboarding pipeline that attackers increasingly exploit. Additionally, customers can now activate products from the AI App Store, a new interface to turn on Abnormal products in a single click. For nearly a decade, Abnormal has protected organizations by understanding behavior, learning what normal looks like for every identity and detecting the deviations that signal anomalous activity or an attack. That behavioral foundation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom